This suggests the need to develop precise screening criteria based on biomarkers such as PD-L1 expression, tumor mutational load, or T-cell infiltration characteristics to optimize therapeutic decision-making for immune checkpoint inhibitors across the full spectrum of prostate cancer stages. The gene discussed is CD274; the disease is neoplasm.